Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 3 study of glecaprevir + pibrentasvir in treatment-naive adults with chronic hepatitis C and compensated cirrhosis
MOH_2017-06-12_000286Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glecaprevir and pibrentasvir in hepatitis C virus infection, sponsored by AbbVie Inc. Primary endpoint: Safety and efficacy assessments. Started Jun 2017; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on MOH_2017-06-12_000286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-12_000286.